Soluble CD30 and Acute Renal Allograft Rejection

Kamali, Koorosh; Abbasi, Mohammad Amin; Abbasi, Ata; Rezaie, Alireza R.

doi:10.5772/26168

Cited by 2 publications

(2 citation statements)

References 68 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researches were carried out confirming their results about pre-transplant sCD30 levels [17], [18]. However, several following studies confirmed that not only elevated pre-transplant but also post-transplant levels sCD30 levels must be measured [7], [19], [20], [21], [22]. Other researches did not find significant of pre/post-sCD30 with the graft function in KT because the very heterogeneous factors that affect this marker [23], [24], [25], [26].…”

Section: Discussionmentioning

confidence: 82%

Assessment of Serum Soluble CD30 Levels in Pediatric Kidney Transplant Recipients

Rashad,

Elshamaa,

Salah

et al. 2023

SEE J Immunol

View full text Add to dashboard Cite

BACKGROUND: CD30 is considered to be a marker for the activated immune system; however, its association with acute rejection and kidney graft function showed severe heterogeneity. AIM: The aim of this study is to examine the predictive value of soluble CD30 (sCD30) levels for kidney transplantation (KT) outcomes in children. MATERIALS AND METHODS: CD30 in serum was measured by ELISA technique in 50 pediatric kidney transplant recipients (KTRs) within 13.4 ± 4.5 days before and within 19.5 ± 9.2 days after KT. sCD30 values were correlated with clinical, laboratory, and immunosuppressive (IS) therapy data and graft function of included patients. Twenty age/gender-matched healthy controls participated as reference values for sCD30 levels. RESULTS: Our study revealed that serum levels of CD30 showed a significant relation between serum sCD30 levels: Pre/post-transplantation (p = 0.02) with increasing sCD30 levels after transplantation (71.60 pg/mL vs. 90.20 pg/mL). In the time, there were no relations between sCD30 with other parameters. CONCLUSIONS: Our results suggest that the measurement of serums CD30 levels may be used as a valuable biomarker in renal transplantation when it is measured pre/post-transplantation.

show abstract

Section: Discussionmentioning

confidence: 82%

Assessment of Serum Soluble CD30 Levels in Pediatric Kidney Transplant Recipients

Rashad,

Elshamaa,

Salah

et al. 2023

SEE J Immunol

View full text Add to dashboard Cite

show abstract

“…The incidence of AR has decreased with availability of potent IS drugs, but it is still a major risk of early graft dysfunction and late allograft loss [ 4 ]. AR can occur at any time after KT but commonly in early post-operative months with declining incidence thereafter [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Multidrug resistant 1 (MDR1) C3435T and G2677T gene polymorphism: impact on the risk of acute rejection in pediatric kidney transplant recipients

et al. 2023

View full text Add to dashboard Cite

Background Tacrolimus is the backbone drug in kidney transplantation. Single nucleotide polymorphism of Multidrug resistant 1 gene can affect tacrolimus metabolism consequently it can affect tacrolimus trough level and incidence of acute rejection. The aim of this study is to investigate the impact of Multidrug resistant 1 gene, C3435T and G2677T Single nucleotide polymorphisms on tacrolimus pharmacokinetics and on the risk of acute rejection in pediatric kidney transplant recipients. Methods Typing of Multidrug resistant 1 gene, C3435T and G2677T gene polymorphism was done using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for 83 pediatric kidney transplant recipients and 80 matched healthy controls. Results In Multidrug resistant 1 gene (C3435T), CC, CT genotypes and C allele were significantly associated with risk of acute rejection when compared to none acute rejection group (P = 0.008, 0.001 and 0.01 respectively). The required tacrolimus doses to achieve trough level were significantly higher among CC than CT than TT genotypes through the 1st 6 months after kidney transplantation. While, in Multidrug resistant 1 gene (G2677T), GT, TT genotypes and T allele were associated with acute rejection when compared to none acute rejection (P = 0.023, 0.033 and 0.028 respectively). The required tacrolimus doses to achieve trough level were significantly higher among TT than GT than GG genotypes through the 1st 6 months after kidney transplantation. Conclusion The C allele, CC and CT genotypes of Multidrug resistant 1 gene (C3435T) and the T allele, GT and TT genotypes of Multidrug resistant 1 gene (G2677T) gene polymorphism may be risk factors for acute rejection and this can be attributed to their effect on tacrolimus pharmacokinetics. Tacrolimus therapy may be tailored according to the recipient genotype for better outcome.

show abstract

Soluble CD30 and Acute Renal Allograft Rejection

Cited by 2 publications

References 68 publications

Assessment of Serum Soluble CD30 Levels in Pediatric Kidney Transplant Recipients

Assessment of Serum Soluble CD30 Levels in Pediatric Kidney Transplant Recipients

Multidrug resistant 1 (MDR1) C3435T and G2677T gene polymorphism: impact on the risk of acute rejection in pediatric kidney transplant recipients

Contact Info

Product

Resources

About